Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence

Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio
June 2009
American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575
Academic Journal
With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we report the current strategies for optimizing treatment outcomes and minimizing the risks of some of the most serious events attributable to infliximab therapy. In particular, an up-to-date overview is provided on how to treat patients with inflammatory bowel disease using infliximab therapy, with regard to the diagnosis and management of latent tuberculosis infection and the risk of reactivation of hepatitis B and C infections. Furthermore, based on the available evidence, we evaluate the possibility of using infliximab during pregnancy. Finally, we evaluate whether patients with malignancies or pre-neoplastic lesions could be candidates for infliximab therapy. Overall, this review will provide physicians who use infliximab for the treatment of inflammatory bowel disease with several practical recommendations for the management of some complex situations that may occur in daily clinical practice.Am J Gastroenterol 2009; 104:1575–1586; doi:10.1038/ajg.2009.162; published online 28 April 2009


Related Articles

  • Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review. Oussalah, Abderrahim; Danese, Silvio; Peyrin-Biroulet, Laurent // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p156 

    The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on...

  • Current Therapeutic Approaches in Inflammatory Bowel Disease. Sohrabpour, Amir Ali; Malekzadeh, Reza; Keshavarzian, Ali // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3668 

    No abstract available.

  • Beyond TNF, Th1 and Th2 in inflammatory bowel disease. Shale, Matthew; Ghosh, Subrata // Gut;Oct2008, Vol. 57 Issue 10, p1349 

    The article focuses on the widespread use of a therapy utilizing antitumour necrosis factor (TNF) monoclonal antibodies for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). It states that other therapies with anticytokines ability are in development, including against...

  • Mucosal Healing and anti TNFs in IBD. Assche, Gert van; Vermeire, S�verine; Rutgeerts, Paul // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p227 

    Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohn's disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids don't induce mucosal healing in Crohn's disease, but...

  • Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Fausel, Rebecca; Afzali, Anita // Therapeutics & Clinical Risk Management;2015, Vol. 11, p63 

    Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and...

  • Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Marzo, Manuela; Felice, Carla; Rapaccini, Gian Lodovico; Guidi, Luisa; Armuzzi, Alessandro // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p15 

    Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical...

  • Infliximab therapy in pediatric Crohn's disease: a review. Parashette, Kalyan Ray; Makam, Raghavendra Charan; Cuffari, Carmen // Clinical & Experimental Gastroenterology;2010, Vol. 3, p57 

    Anti-tumor necrosis factor alpha (TNF-α) therapy has re-defined our treatment paradigms in managing patients with Crohn's disease (CD) and ulcerative colitis. Although the ACCENT studies showed proven efficacy in the induction and maintenance of disease remission in adult patients with...

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease. Rutella, Sergio; Fiorino, Gionata; Vetrano, Stefania; Correale, Carmen; Spinelli, Antonino; Pagano, Nico; Arena, Vincenzo; Maggiano, Nicola; Repici, Alessandro; Malesci, Alberto; Danese, Silvio // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p762 

    OBJECTIVES:Inflammation-driven angiogenesis contributes to the pathogenesis of inflammatory bowel disease (IBD). In line with this, the efficacy of inhibitors of angiogenesis has been demonstrated in experimental models of colitis. Currently, the ability of infliximab, an anti-tumor necrosis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics